Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia
13 août 2020 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020
07 août 2020 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting
29 mai 2020 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports First Quarter 2020 Financial Results
15 mai 2020 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop...
Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting
13 mai 2020 17h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020
08 mai 2020 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting
27 avr. 2020 09h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON , April 27, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop...
Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting
13 avr. 2020 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, April 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Appoints Ernst & Young as New Auditor
11 mars 2020 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Full Year 2019 Financial Results
06 mars 2020 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, March 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...